Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy

References

• nccn.org [Internet]. Plymouth Meeting, PA: National Comprehensive Cancer Network [cited 2020 May 6]. Available from: https://www.nccn.org/patients/guidelines/content/PDF/prostate-patient.pdf
   Google Scholar
• Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385–395.
   PubMed Web of Science ®Google Scholar
• Nicosia L, Mazzola R, Rigo M, et al. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. J Cancer Res Clin Oncol. 2019;145(10):2547–2554.
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060.
   PubMed Web of Science ®Google Scholar
• Alongi F, Cozzi L, Arcangeli S, et al. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol. 2013;8:171.
   PubMed Web of Science ®Google Scholar
• Duffton A, Sadozye A, Devlin L, et al. Safety and feasibility of prostate stereotactic ablative radiotherapy using multimodality imaging and flattening filter free. Br J Radiol. 2018;91(1084):20170625.
   PubMed Web of Science ®Google Scholar
• de Muinck Keizer DM, Pathmanathan AU, Andreychenko A, et al. Fiducial marker based intra-fraction motion assessment on cine-MR for MR-linac treatment of prostate cancer. Phys Med Biol. 2019;64(7):07NT02.
   PubMed Web of Science ®Google Scholar
• O'Neill AG, Jain S, Hounsell AR, et al. Fiducial marker guided prostate radiotherapy: a review. Br J Radiol. 2016;89(1068):20160296.
   PubMed Web of Science ®Google Scholar
• Devlin L, Dodds D, Sadozye A, et al. Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy. Br J Radiol. 2020;93(1108):20190789.
   PubMed Web of Science ®Google Scholar
• Corradini S, Alongi F, Andratschke N, et al. MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol. 2019;14(1):92.
   PubMed Web of Science ®Google Scholar
• Alongi F, Rigo M, Figlia V, et al. 1.5T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol. 2020;15(1):69.
   PubMed Web of Science ®Google Scholar
• Alongi F, Mazzola R, Fiorentino A, et al. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer . Strahlenther Onkol. 2019;195(2):113–120.
   PubMed Web of Science ®Google Scholar
• Ruggieri R, Naccarato S, Stavrev P, et al. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. Br J Radiol. 2015;88(1054):20140736.
   PubMed Web of Science ®Google Scholar
• Winkel D, Bol GH, Kroon PS, et al. Adaptive radiotherapy: the Elekta Unity MR-linac concept. Clin Transl Radiat Oncol. 2019;18:54–59.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Baus WW, Blanck O, et al. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol. 2020;196(5):417–420.
   PubMed Web of Science ®Google Scholar
• Wahl M, Descovich M, Shugard E, et al. Interfraction anatomical variability can lead to significantly increased rectal dose for patients undergoing stereotactic body radiotherapy for prostate cancer. Technol Cancer Res Treat. 2017;16(2):178–187.
   PubMed Web of Science ®Google Scholar
• Pearson D, Gill SK, Campbell N, et al. Dosimetric and volumetric changes in the rectum and bladder in patients receiving CBCT-guided prostate IMRT: analysis based on daily CBCT dose calculation. J Appl Clin Med Phys. 2016;17(6):107–117.
   PubMed Web of Science ®Google Scholar
• Cheng CW, Das IJ. Treatment plan evaluation using dose-volume histogram (DVH) and spatial dose-volume histogram (zDVH). Int J Radiat Oncol Biol Phys. 1999;43(5):1143–1150.
   PubMed Web of Science ®Google Scholar
• Hatton JA, Greer PB, Tang C, et al. Does the planning dose-volume histogram represent treatment doses in image-guided prostate radiation therapy? Assessment with cone-beam computerised tomography scans. Radiother Oncol. 2011;98(2):162–168.
   PubMed Web of Science ®Google Scholar
• Varadhan R, Hui SK, Way S, et al. Assessing prostate, bladder and rectal doses during image guided radiation therapy-need for plan adaptation? J Appl Clin Med Phys. 2009;10(3):2883.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Langen KM, Zeidan OA, et al. Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66(3):876–882.
   PubMed Web of Science ®Google Scholar
• Zilli T, Franzese C, Bottero M, et al. Single fraction urethra-sparing prostate cancer SBRT: phase I results of the ONE SHOT trial. Radiother Oncol. 2019;139:83–86.
   PubMed Web of Science ®Google Scholar